Please login to the form below

Not currently logged in
Email:
Password:

ezetimibe/simvastatin

This page shows the latest ezetimibe/simvastatin news and features for those working in and with pharma, biotech and healthcare.

Merck's ezetimibe has 'modest' benefit when added to statins

Merck's ezetimibe has 'modest' benefit when added to statins

The IMPROVE-IT trial was designed to compare the effects of Vytorin (simvastatin and ezetimibe) versus Zocor (simvastatin) on cardiovascular complications and death in 18, 000 post-ACS patients and got ... any impact on the development of atherosclerosis

Latest news

  • Merck profit slides as generics continue to bite Merck profit slides as generics continue to bite

    and Vytorin (ezetimibe and simvastatin) were up only marginally to $1.07bn, with gains for Zetia balancing Vytorin declines. ... Merck is hoping to re-inject growth into the cholesterol franchise with the ongoing roll-out of Liptruzet (ezetimibe and

  • Merck forges on with Vytorin trial after safety review Merck forges on with Vytorin trial after safety review

    The IMPROVE-IT study is comparing Vytorin (simvastatin and ezetimibe) to Zocor (simvastatin) in 18, 000 patients and has been cleared to continue after an independent monitoring board concluded there were ... year. It is trying to show a benefit for the

  • Merck settles Vytorin lawsuit for $688m Merck settles Vytorin lawsuit for $688m

    case. At the heart of the dispute was Merck's controversial ENHANCE trial of Vytorin (ezetimibe plus simvastatin), which compared the combination to simvastatin alone in preventing the progression of atherosclerosis. ... sales of Vytorin and monotherapy

  • Merck blocks Mylan’s generic Zetia and Vytorin after appeal Merck blocks Mylan’s generic Zetia and Vytorin after appeal

    ezetimibe, which is contained in both products, was “ valid and enforceable” until its expiration in April 2017. ... Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin), which are approved in the US to reduce cholesterol, are big sellers for Merck,

  • Merck & Co stops development of Januvia, atorvastatin combo Merck & Co stops development of Januvia, atorvastatin combo

    to approve MK-0653c, a fixed-dose tablet based on ezetimibe and atorvastatin. ... The company has also seen declining sales of its premium Vytorin (ezetimibe plus simvastatin) combination product, with sales down 7 per cent to $1.9bn in the first nine

More from news
Approximately 3 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics